Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen

Overview

Description
A component of a live influenza vaccine that utilizes weakened influenza virus to generate an immune response.
Description
A component of a live influenza vaccine that utilizes weakened influenza virus to generate an immune response.
DrugBank ID
DB18661
Type
Biotech
US Approved
YES
Other Approved
NO
Clinical Trials
Phase 0
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Identification

Summary

Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is a component of a live attenuated influenza vaccine.

Brand Names
FluMist, FluMist Quadrivalent
Generic Name
Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen
DrugBank Accession Number
DB18661
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen". This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

There are three basic types of vaccines available: inactivated influenza vaccine (IIV), live attenuated influenza vaccine (LAIV), and recombinant influenza vaccines (RIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Acetylsalicylic acidThe risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Acetylsalicylic acid.
Aminosalicylic acidThe risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Aminosalicylic acid.
BalsalazideThe risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Balsalazide.
Bismuth subsalicylateThe risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Bismuth subsalicylate.
Choline salicylateThe risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Choline salicylate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FluMistInfluenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole (10000000 [FFU]/0.2mL) + Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen (10000000 [FFU]/0.2mL)SprayNasalMedImmune, LLC2024-08-06Not applicableUS flag
FluMist QuadrivalentInfluenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen (10000000 [FFU]/0.2mL)SprayNasalMedImmune, LLC2023-08-142025-03-03US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
RxNav
2645084

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SprayNasal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 10, 2023 20:29 / Updated at October 11, 2023 10:34